Related Experiment Video
Updated: Jul 18, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Combined-modality strategy for gastrointestinal stromal tumors
1Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH 03756, USA. burton.1.eisenberg@dartmouth.edu
Abstract:
Gastrointestinal stromal tumor (GIST) is the most common nonepithelial tumor of the gastrointestinal tract. The majority of these tumors stain positive for the CD117 antigen to the KIT protein and have become a well-documented clinical entity. The dysregulated KIT protein is oncogenic and is an ideal target for imatinib, a KIT-selective inhibitor. Clinical trials of imatinib for metastatic GIST have shown either partial response or long-duration stable disease in 82% of patients. Trials addressing the efficacy of adjuvant imatinib following resection for high-risk primary GIST are awaiting results. The neoadjuvant preoperative use of imatinib to provide pharmacologic debulking and long-term disease control is also nearing completion in a clinical trial. This trial has the potential of addressing whether the combination of surgery and imatinib can enhance organ sparing, decrease drug resistance, and prolong disease-free and overall survival. The continued study of combining surgery and a target-specific agent for malignant GIST will be a valuable reference for future strategies combining surgery and targeted treatment in other solid tumors.
Insights
Imatinib therapy shows significant efficacy in treating metastatic gastrointestinal stromal tumors (GIST), with ongoing trials exploring its use in neoadjuvant and adjuvant settings to improve outcomes.
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Molecular Targeted Therapy
Background:
- Gastrointestinal stromal tumor (GIST) is the most common nonepithelial gastrointestinal malignancy.
- Most GISTs express the CD117 antigen, indicating KIT protein activation.
- Dysregulated KIT protein is a key oncogenic driver in GIST.
Purpose of the Study:
- To evaluate the efficacy of imatinib, a KIT-selective inhibitor, in managing GIST.
- To assess the potential benefits of neoadjuvant and adjuvant imatinib in combination with surgery.
- To explore imatinib's role in enhancing organ sparing and prolonging survival in high-risk GIST.
Main Methods:
- Review of clinical trials investigating imatinib for metastatic and primary GIST.
- Analysis of outcomes from trials assessing neoadjuvant imatinib for pharmacologic debulking.
- Evaluation of ongoing trials for adjuvant imatinib following surgical resection.
Main Results:
- Imatinib demonstrated partial response or stable disease in 82% of patients with metastatic GIST.
- Clinical trials are evaluating the efficacy of adjuvant and neoadjuvant imatinib.
- Combination therapy with surgery and imatinib is being studied for improved survival and reduced resistance.
Conclusions:
- Imatinib is a highly effective targeted therapy for GIST.
- Neoadjuvant and adjuvant imatinib, combined with surgery, hold promise for improving GIST treatment outcomes.
- This approach may serve as a model for targeted therapy combinations in other solid tumors.
